Can you provide the last earnings date for INOVIO PHARMACEUTICALS INC?
INOVIO PHARMACEUTICALS INC (INO) last reported earnings on 3/12/2026.
NASDAQ:INO • US45773H4092
Past quarterly earnings results for INOVIO PHARMACEUTICALS INC (INO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.06 | -0.36 | 116.60% | 110.00% | - | -100.00% | ||
| Q3 2025 | -0.87 | -0.43 | -103.56% | 2.25% | - | - | ||
| Q2 2025 | -0.61 | -0.62 | 0.86% | 48.74% | - | -100.00% | ||
| Q1 2025 | -0.41 | -0.75 | 44.99% | 68.70% | 65K | - | - | |
| Q4 2024 | -0.60 | -0.85 | 29.03% | 46.43% | 117K | 30.3K | 286.14% | 13.98% |
| Q3 2024 | -0.89 | -1.16 | 23.41% | 42.95% | 105.545K | -100.00% | -100.00% | |
| Q2 2024 | -1.19 | -1.11 | -6.95% | 23.72% | 100.76K | 122.715K | -17.89% | -55.41% |
| Q1 2024 | -1.31 | -1.01 | -29.26% | 31.77% | 152.308K | -100.00% | -100.00% | |
| Q4 2023 | -1.12 | -1.28 | 12.51% | 55.56% | 102.65K | 347.642K | -70.47% | -17.88% |
| Q3 2023 | -1.56 | -1.54 | -1.61% | 13.33% | 388K | 117.837K | 229.27% | -95.76% |
| Q2 2023 | -1.56 | -1.76 | 11.23% | 71.74% | 225.97K | 265.125K | -14.77% | -71.18% |
| Q1 2023 | -1.92 | -1.76 | -9.25% | 55.56% | 114K | 277.75K | -58.96% | -42.71% |
| Q4 2022 | -2.52 | -2.04 | -23.76% | 58.00% | 125K | 342.592K | -63.51% | -85.10% |
| Q3 2022 | -1.80 | -3.58 | 49.78% | 48.28% | 9.154M | 629.402K | 1,354.40% | 3,034.93% |
| Q2 2022 | -5.52 | -3.78 | -46.13% | -17.95% | 784K | 525.877K | 49.08% | 187.18% |
| Q1 2022 | -4.32 | -4.16 | -3.82% | -33.33% | 199K | 678.387K | -70.67% | -46.36% |
| Q4 2021 | -6.00 | -3.86 | -55.24% | -257.14% | 839K | 2.865M | -70.72% | -84.97% |
| Q3 2021 | -3.48 | -3.95 | 11.92% | -363.64% | 292K | 980.377K | -70.22% | 23.73% |
| Q2 2021 | -4.68 | -3.02 | -55.08% | 54.12% | 273K | 1.224M | -77.70% | 2.25% |
| Q1 2021 | -3.24 | -2.20 | -47.34% | -22.73% | 371K | 863.691K | -57.04% | -72.04% |
| Q4 2020 | -1.68 | -2.69 | 37.62% | - | 5.581M | 1.123M | 396.97% | - |
| Q3 2020 | 1.32 | -2.29 | 157.70% | - | 236K | 3.077M | -92.33% | - |
| Q2 2020 | -10.20 | -2.05 | -398.72% | - | 267K | 2.634M | -89.86% | - |
| Q1 2020 | -2.64 | -2.73 | 3.19% | - | 1.327M | 1.932M | -31.31% | - |
Notes
INOVIO PHARMACEUTICALS INC (INO) last reported earnings on 3/12/2026.
INOVIO PHARMACEUTICALS INC (INO) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, INOVIO PHARMACEUTICALS INC (INO) has beaten EPS estimates in 3 out of 4 releases.